Memorial Sloan-Kettering team, including Department of Surgery Chair Peter Scardino, disagrees with new PSA screening recommendations recently released by government task force.
The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.
Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.
The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.
The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.
Researchers at Memorial Sloan-Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.
